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GRAPHICAL ABSTRACT 
 
Abbreviations: mITT= microbiological intent-to-treat; MRSA=methicillin-resistant S. aureus; MSSA=methicillin-sensitive 
S. aureus. 
Note: The p-values for the MRSA and MSSA subgroups are ad-hoc p-values. 
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ABSTRACT 
BACKGROUND 
Novel therapeutic approaches are critically needed for Staphylococcus aureus bloodstream infections 
(BSI), particularly for methicillin-resistant S. aureus (MRSA). Exebacase, a first-in-class 
antistaphylococcal lysin, is a direct lytic agent that is rapidly bacteriolytic, eradicates biofilms, and 
synergizes with antibiotics. 
METHODS 
In this superiority-design study, we randomly assigned 121 patients with S. aureus BSI/endocarditis to 
receive a single dose of exebacase or placebo. All patients received standard-of-care antibiotics. The 
primary efficacy endpoint was clinical outcome (responder rate) at Day 14. 
RESULTS 
Clinical responder rates at Day 14 were 70.4% and 60.0% in the exebacase + antibiotics and antibiotics 
alone groups, respectively (difference=10.4, 90% CI [-6.3, 27.2], p-value=0.31), and were 
42.8 percentage points higher in the pre-specified exploratory MRSA subgroup (74.1% vs. 31.3%, 
difference=42.8, 90% CI [14.3, 71.4], ad hoc p-value=0.01). Rates of adverse events (AEs) were similar 
in both groups. No AEs of hypersensitivity to exebacase were reported. Thirty-day all-cause mortality 
rates were 9.7% and 12.8% in the exebacase + antibiotics and antibiotics alone groups, respectively, with 
a notable difference in MRSA (3.7% vs. 25.0%, difference= –21.3, 90% CI [-45.1, 2.5], ad hoc p-
value=0.06). Among MRSA patients in the United States, median length-of-stay was 4-days shorter and 
30-day hospital readmission rates were 48 percentage points lower in the exebacase-treated group 
compared with antibiotics alone. 
CONCLUSIONS 
This study establishes proof-of-concept for exebacase and direct lytic agents as potential therapeutics and 
supports conduct of a confirmatory study focused on exebacase to treat MRSA BSI. 
TRIAL REGISTRATION: Clinicaltrials.gov NCT03163446 
FUNDING: ContraFect Corporation.  
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INTRODUCTION 
Complicated Staphylococcus aureus (S. aureus) bloodstream infections (BSI) cause substantial morbidity 
and mortality (1), which is highest for methicillin resistant S. aureus (MRSA) BSI (2, 3, 4, 5). Mortality 
rates for patients with S. aureus BSI have not changed significantly for decades despite new antibiotics 
with activity against MRSA (6, 7, 8). Hence, there is an urgent need for novel approaches to improve 
clinical outcomes for S. aureus BSI, particularly MRSA. 
Exebacase, an antistaphylococcal lysin, is an entirely new antibacterial treatment modality (9, 10). As a 
peptidoglycan hydrolase, recombinantly-produced as a purified protein, exebacase results in rapid, 
pathogen-targeted bacteriolysis, potent biofilm eradication, synergy with antibiotics, low propensity for 
resistance, and the potential to suppress antibiotic resistance when used together with antibiotics 
(9, 10, 11, 12). Exebacase represents a first-in-field, first-in-class, non-antibiotic antimicrobial direct lytic 
agent with the potential to improve clinical outcomes of S. aureus BSI. Here, we report the safety and 
efficacy of exebacase used in addition to standard antibiotic therapy to treat S. aureus BSI including 
endocarditis in a superiority-design, proof-of-concept study. 
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RESULTS 
Trial Population 
This randomized, double-blind, placebo-controlled, superiority-design, first-in-patient, proof-of-concept 
study (clinicaltrials.gov identifier: NCT03163446) was conducted at 42 sites in 11 countries between 
May 2017 and March 2019. A total of 3729 patients were pre-screened for eligibility, of which 
121 patients were randomized (intent-to-treat [ITT] population), 119 patients received study drug 
(exebacase or placebo) (safety population), and 116 patients had confirmed S. aureus BSI and were 
included in the primary efficacy analysis population (the microbiological intent-to-treat [mITT] 
population) (Figure 1). The majority of patients were enrolled in the United States (U.S.) (79.3%). Small 
numbers of patients were enrolled in each of the other 10 countries. The average patient was 
approximately 56 years of age, white (68.1%), and male (67.2%). 
Approximately one-third of patients in both treatment groups had MRSA (Table 1) resulting in 27 and 
16 patients in the MRSA subgroup in the exebacase + antibiotics group and the antibiotics alone group, 
respectively. More than twice as many patients in the exebacase + antibiotics group compared with the 
antibiotics alone group had left-sided endocarditis (15.5% vs. 6.7%) and uncomplicated BSI (18.3% vs. 
6.7%). Renal and cardiovascular comorbidities were also more common in the exebacase + antibiotics 
group compared to the antibiotics alone group: 56.3% and 37.8% had moderate to severe renal 
insufficiency, 71.8% and 53.3% had diabetes, and 38.0% and 27.8% had more than one baseline cardiac 
diagnosis, respectively. Among patients with BSI, the most common source of infection was skin and soft 
tissue in the exebacase + antibiotics group and intravascular (hemodialysis access or other catheter) in the 
antibiotics alone group. In the MSSA subgroup, 8 (18.2%) patients in the exebacase + antibiotics group 
compared with 3 (10.0%) patients in the antibiotics alone group had left-sided endocarditis. There were 
other clinically important differences between the exebacase + antibiotics and antibiotics alone groups 
with respect to baseline comorbidities including moderate to severe renal insufficiency (61.4% vs. 
40.0%), poorly controlled diabetes (36.4% vs. 16.7%), and hypertension (75.0% vs. 56.7%). 
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All patients in the mITT population received an antibiotic to which the baseline pathogen was susceptible 
within 2 days of study drug administration. Vancomycin and beta-lactams were the most frequently used 
antibiotics through Day 14. The median duration of antibiotic therapy from the start of study drug was the 
same in both treatment groups (29 days, range: 2 to 181 days and 2 to 91 days in the exebacase + 
antibiotics and antibiotics alone groups, respectively) (Table 2). 
Efficacy Analyses 
In the mITT population, 70.4% of the exebacase + antibiotics and 60.0% of the antibiotics alone groups 
were clinical responders at Day 14 (difference=10.4, 90% CI [-6.3, 27.2], p-value=0.31) (Table 3). In the 
pre-specified exploratory MRSA subgroup, the clinical responder rate at Day 14 was 42.8 percentage 
points higher among exebacase-treated patients compared to those who received antibiotics alone (74.1% 
vs. 31.3%, difference=42.8, 90% CI [14.3, 71.4], ad hoc p-value=0.01). Responder rates in the 
methicillin-sensitive S. aureus (MSSA) subgroup were similar between treatment groups. There was 
1 patient in the antibiotics alone group who had both MRSA and MSSA and was counted in each 
subgroup for the analyses. A sensitivity analysis was completed whereby this patient was excluded from 
the MRSA and MSSA subgroup analyses. Since this patient was a non-responder, the responder rate in 
the antibiotics alone group increased slightly, however, the conclusions were unchanged. The exploratory 
analysis of clinical outcome at Day 14 in the clinically evaluable population is provided in Supplemental 
Table 1 available online with this article. 
The disproportionately high number of left-sided endocarditis patients randomized to exebacase appeared 
to affect the efficacy analysis due to the inherent lethality of this disease. An ad hoc analysis of patients 
with BSI/right-sided endocarditis (i.e., excluding left-sided endocarditis) (Figure 2) found 80.0% and 
59.5% of patients in the exebacase + antibiotics and antibiotics alone groups, respectively, were clinical 
responders (difference=20.5, 90% CI [3.4, 37.6], ad hoc p-value=0.03). Results in MRSA patients with 
BSI/right-sided endocarditis were similar to the overall MRSA population.  
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The clinical response pattern observed at Day 14 persisted at subsequent timepoints in both the mITT 
population and MRSA and MSSA subgroups (Table 3). A bar graph showing clinical outcome at Day 7, 
Day 14, EOT, and TOC is provided in Supplemental Figure 1 available online with this article). 
Microbiological response was similar between the exebacase + antibiotics and antibiotics alone groups at 
Day 7 (83.1% vs. 86.7%) and Day 14 (90.1% vs. 84.4%). In the MRSA subgroup, microbiologic response 
at Day 14 in the exebacase + antibiotics and antibiotics alone groups was 92.6% vs.75.0%, and in patients 
with MSSA, 88.6% vs. 90.0%. All patients that were clinical responders at Day 14 had negative blood 
cultures by Day 14. The exploratory analysis of microbiologic response at Days 7 and 14 in the 
microbiologically evaluable population is provided in Supplemental Table 2 available online with this 
article. 
Kaplan-Meier curves of time to symptom resolution, time to defervesence, and time to clearance of 
bacteremia are in Supplemental Figures 2, 3, and 4, respectively, available online with this article. 
Safety Analyses 
The incidence of treatment-emergent adverse events (TEAEs) and serious TEAEs was similar in both 
groups (Table 4). No TEAEs of hypersensitivity to exebacase were reported, and no TEAEs resulted in 
withdrawal of study drug. One serious TEAE, which occurred on Day 30 after exebacase dosing, was 
considered related to study drug by an investigator. The 30-day all-cause mortality rate was 9.7% (7/72) 
and 12.8% (6/47) in the exebacase + antibiotics and antibiotics alone groups. In the MRSA subgroup, the 
30-day all-cause mortality rate was 3.7% (1/27) in the exebacase + antibiotics group and 25.0% (4/16) in 
the antibiotics alone group (difference= –21.3, 90% CI [-45.1, 2.5], ad hoc p-value=0.06). Through test-
of-cure (TOC), which occurred 28 days after the end-of-treatment with antibiotics (EOT), mortality rates 
were 19.4% (14/72) and 14.9% (7/47) in the exebacase + antibiotics and antibiotics alone groups, 
respectively (difference= 4.6, 90% CI [-8.7, 17.8], ad hoc p-value=0.63); a similar trend was observed 
through Day 180. 
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Immunogenicity 
At baseline, 20.8% and 14.9% of patients had pre-existing exebacase cross-reactive anti-drug antibodies 
(ADA) in the exebacase + antibiotics and antibiotics alone groups, respectively (Table 5). Clinical 
responder rates at Day 14 were similar among exebacase patients who were ADA-positive and ADA-
negative at baseline (73.3% and 69.6%, respectively), as were TEAE rates (100.0% and 91.2%, 
respectively). Of patients who were ADA-negative at baseline and had evaluable post-dose ADA 
samples, 71.2% (37/52) of exebacase-treated patients and 25.0% (8/32) in the antibiotics alone group 
developed treatment-emergent ADA. 
One patient had detectable, low titer exebacase-cross reactive immunoglobulin E (IgE) at baseline, which 
remained low after dosing with exebacase. Six patients who received exebacase and none who received 
antibiotics alone developed treatment-emergent IgE, which were of low titer and transient. 
Health Resource Utilization 
Among U.S. patients with MRSA who were alive at hospital discharge, the median length-of-stay was 
6 days in the exebacase + antibiotics group compared with 10 days in the antibiotics alone group 
(Table 6). All-cause 30-day readmissions occurred in 16.0% and 30.8% of patients in the exebacase + 
antibiotics and antibiotics alone groups, respectively. Among U.S. patients with MSSA who were alive at 
hospital discharge, the median length-of-stay was 8 and 7 days in the exebacase + antibiotics and 
antibiotics alone groups, respectively; all-cause 30-day readmissions occurred in 27.6% and 43.5% of 
patients in the exebacase + antibiotics and antibiotics alone groups, respectively. 
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DISCUSSION 
Exebacase, a first-in-class direct lytic agent, is an entirely new modality for treatment of serious 
infections caused by S. aureus and a member of a new class of non-antibiotic antimicrobials known as 
lysins (cell wall hydrolase enzymes), which may represent the post-antibiotic generation of 
treatments (9, 10). 
This first-in-patient, proof-of-concept study tested the utility of exebacase as adjunctive therapy to 
improve clinical outcomes for S. aureus BSI including endocarditis. Since exebacase was added to 
standard-of-care antibiotics, this study utilized a superiority design uncommon in contemporary antibiotic 
drug development, which typically compares investigational antibiotic vs. standard antibiotic in a 
noninferiority design). While a treatment difference of 10 percentage points was observed in the 
mITT population at Day 14 (70.4% vs. 60.0%), treatment with exebacase was associated with a 
42.8 percentage point higher clinical responder rate in the MRSA subgroup at the primary Day 14 
efficacy timepoint (74.1% vs. 31.3%). The higher responder rates among MRSA patients that received 
exebacase were sustained at later time points and are supported by reductions in length-of-stay and 
readmission rates. Responder rates in the MSSA subgroup were similar between treatment groups. The 
low responder rate of 31.3% among MRSA patients in the placebo group is consistent with historically 
worse outcomes with MRSA, compared with MSSA, and allows for the larger treatment difference in 
patients with MRSA. Based on in vitro microbiologic studies and contemporary surveillance studies 
(13, 14), which demonstrate similar activity of exebacase against MRSA and MSSA, there is no evidence 
of inherent underlying biologic differences in the activity of exebacase against MRSA and MSSA. 
However, while exebacase exhibited no biological differences by itself against MRSA and MRSA, the 
biological effects of antibiotics used to treat MRSA and MSSA (e.g., vancomycin vs beta-lactam) to 
which exebacase was added are very different.  Therefore, it is possible that the additive effect of 
exebacase in patients with MRSA may be due to the drugs to which it is added. The differences in 
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responder rates in the MSSA subgroup may have also been influenced by differences in underlying 
serious comorbidities and the distribution of left-sided endocarditis between treatment groups. 
The results of this study have several key implications. Complicated S. aureus BSI are serious, common, 
and potentially lethal infections (15), and MRSA has been identified as a serious threat by both the 
Centers for Disease Control and the World Health Organization (16, 17). The introduction of 
vancomycin, a major advance in the treatment of MRSA bacteremia, was over 60 years ago. Daptomycin, 
the newest drug developed for S. aureus BSI, is over 13 years old and was approved based on 
noninferiority to older antibiotics, with MRSA clinical success rates of 44.4% for daptomycin and 31.8% 
for vancomycin (18). Subsequent attempts to develop new antibiotics for S. aureus bacteremia have failed 
(19, 20). The addition of adjunctive agents such as immunotherapeutics (21, 22, 23, 24) or antibiotics 
(e.g., gentamicin [25], rifampin [26], or beta-lactams [27]) to standard therapy for S. aureus or MRSA 
BSI has generally shown disappointing results in clinical trials with the exception of a recent open-label 
pilot study of the initial combination of daptomycin and ceftaroline, which showed potentially promising 
results to be confirmed in a larger randomized clinical trial (28). Thus, the urgent need for effective new 
treatments for S. aureus BSI, and MRSA BSI in particular, remains unaddressed. 
Based on the novel properties of lysins which are complimentary to and synergistic with antibiotics 
(9, 10, 11, 12, 33), and the unmet need for agents to improve clinical outcomes for S. aureus 
BSI/endocarditis associated with conventional antibiotics alone, exebacase is being developed as 
adjunctive therapy. The current study is the first to show promising improvements in clinical outcomes 
among patients with S. aureus BSI who received adjunctive lysin therapy. This improvement was 
particularly marked in the pre-specified exploratory MRSA subgroup. Exebacase was generally safe and 
well tolerated, with adverse events consistent with those expected in critically ill, hospitalized patients 
with potentially life-threatening S. aureus BSI, including endocarditis and/or underlying comorbid 
conditions. Overall, 30-day all-cause mortality rate was 9.7% in the exebacase-treated group and 12.8% in 
the antibiotics alone group, with a greater difference in the MRSA subgroup (3.7% vs. 25.0%). These 
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findings are important considering that 28-day mortality has been used as a standard for assessment of 
survival in hospitalized patients with serious infections (e.g., hospital-acquired and ventilator-associated 
bacterial pneumonia [HABP/VABP]) (29, 30), and is an FDA-recommended endpoint in HABP/VABP 
trials (31). All-cause mortality rates in both groups were higher at the TOC timepoint, which varied 
widely between patients (up to 180 days after dosing) allowing time for mortality due to medical events 
unrelated to the infection under study. The TOC all-cause mortality rates of 19.4% and 14.9% in the 
exebacase + antibiotics and antibiotics alone groups may have been affected by the higher number of 
comorbidities and patients with left-sided endocarditis in the exebacase-treated group. 
Importantly, no hypersensitivity reactions to exebacase were reported, despite the fact that 20% of 
exebacase-treated patients had baseline exebacase ADA. The pre-existing ADA did not affect efficacy or 
safety outcomes and exebacase does not appear to be sensitizing for allergic hypersensitivity. The 
presence of baseline antibodies to exebacase may be explained by recent findings that exposures to 
S. aureus (and likely other pathogens, including streptococci) results in human antibody responses against 
a range of cell wall proteins, including autolysins (32), which would be expected to share common 
structural motifs and antigenic domains with exebacase. Prior exposures to staphylococci or streptococci 
(and the generation of antibodies) may occur during the course of infection, or during carriage of these 
organisms in microbiome environments. 
Among U.S. patients with MRSA, exebacase was associated with lower median length-of-stay and 30-
day hospital readmission rates compared with antibiotics alone. This orthogonal analysis further supports 
the clinical efficacy observed in the MRSA subgroup. While the precise drivers of these reductions in 
health resource utilization are not known, the hallmark antibacterial actions of exebacase, including rapid 
bactericidality, eradication of S. aureus biofilms, and potent synergy with antibiotics which have been 
well described in vivo and in vitro (9, 10, 11, 12, 33) may have played a role. 
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A limitation of the study was the relatively small sample size, especially in the MRSA subset, given this 
was a first-in-patient, proof-of-concept rather than a confirmatory study. The sample size for the MRSA 
subset was not pre-specified since the analysis in this population was an exploratory objective of the 
protocol. Another limitation was the difference in the proportion of patients with left-sided endocarditis 
and uncomplicated BSI between treatment groups. The baseline difference in left-sided endocarditis may 
have affected the efficacy and safety analyses, given that these patients have poor outcomes and generally 
require surgical intervention. The results in the MSSA subset may also be difficult to interpret given 
differences between treatment groups in clinically important serious underlying comorbidities. In 
addition, EOT and TOC were not fixed time points, which may affect the interpretation of the efficacy 
findings at these timepoints. The 30-day mortality rates in this study were lower than those seen in cohort 
studies (1, 6), but are similar to mortality rates in recent clinical trials of S. aureus bacteremia (18, 20, 
27). This difference in mortality rates in cohort studies vs. interventional trials reflects the intrinsic 
difference in the purpose of clinical medicine vs. clinical trials. Because clinical trials primarily seek to 
evaluate the efficacy of a product, stringent inclusion/exclusion criteria are in place to exclude those 
patients who are likely to have poor clinical outcome due to factors unrelated to S. aureus BSI (e.g., 
malignancy). Given the unmet medical need to improve the clinical success rates for S. aureus/MRSA 
BSI with antibiotics alone, this study evaluated exebacase used in addition to standard therapy. The 
efficacy of exebacase as a monotherapy was not evaluated in this study. The potential use of exebacase as 
monotherapy could be explored, as appropriate, for discrete clinical problems for which standard 
antibiotic therapy is not available (e.g., resistant pathogens). 
In summary, this study establishes proof-of-concept for exebacase and the emerging new class of direct 
lytic agents as potential therapeutics for BSI caused by MRSA. Moreover, these data support the testing 
of exebacase in a confirmatory study with a focus on MRSA. Given the consistently poor outcomes of 
MRSA BSI treated with standard antibiotic therapy and the long list of failed attempts to develop new 
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treatments, these data suggest that exebacase may be the first tangible opportunity in decades to improve 
clinical responder rates and reduce mortality for MRSA BSI. 
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METHODS 
Trial Design and Oversight 
An independent Data Safety Monitoring Board reviewed unblinded safety and pharmacokinetic data at 
pre-specified points. Clinical response was assessed by the investigator. An independent, blinded 
Adjudication Committee adjudicated eligibility, final diagnosis including endocarditis determination, and 
clinical response. Echocardiograms were adjudicated by a blinded cardiologist at an echocardiography 
laboratory according to standard methodology (34). S. aureus identification and susceptibility were 
confirmed by a central microbiology laboratory. 
ContraFect Corporation, as study Sponsor, designed and conducted the study in collaboration with the 
principal investigator. ContraFect prepared the statistical analysis plan, conducted the analyses, and 
interpreted the data in conjunction with the authors. The protocol is included in the supplemental material 
available online with this article. 
Patient Population and Treatment 
Eligible patients were at least 18 years of age, met screening criteria, and had Gram-positive cocci in 
clusters on Gram stain plus positive direct tube coagulase test or blood culture positive for S. aureus 
within 72 hours before randomization. Echocardiography was performed within 3 days of 
randomization (35). Removable sources of infection (e.g., intravascular line, abscess, dialysis graft) were 
removed or debrided within 72 hours after randomization. All patients received antibiotics selected by the 
investigator according to the protocol consisting of semisynthetic penicillins or first-generation 
cephalosporins for MSSA and vancomycin or daptomycin for MRSA. Patients were randomly assigned in 
a 3:2 ratio using a blocked randomization scheme to receive a single 2-hour intravenous infusion of 
blinded study drug (exebacase or placebo). A 3:2 randomization ratio was used so as to expose a larger 
proportion of patients to exebacase compared to placebo, but also maximize the sample size in the 
placebo group. Exebacase was dosed at 0.25 mg/kg based on target attainment studies in animals and 
Phase 1 data in humans. While the study was ongoing, review of PK data by the Data Safety Monitoring 
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Board resulted in dose adjustment to 0.12 mg/kg for patients with creatinine clearance <60 mL/min 
and/or age >50. 
Analysis Population, Endpoints, and Assessments 
The ITT population included all randomized patients. The safety population included all patients who 
received study drug. The primary efficacy analysis population, mITT, included all patients with 
confirmed S. aureus BSI who received study drug. 
Patient assessments occurred at Day 7, Day 14, EOT, and TOC 28 days after EOT, with long-term 
follow-up of immunogenicity and safety at Day 180 after study drug dosing. 
The primary objectives were to describe safety and tolerability and estimate clinical outcome at Day 14 of 
exebacase + antibiotics compared with antibiotics alone. Day 14 was selected as the primary efficacy 
endpoint because it was hypothesized that exebacase’s novel, rapid mechanism of action and hallmark 
properties (9, 10, 11, 12, 33) would lead to a more rapid resolution of clinical signs and symptoms of 
infection. The Day 14 timepoint allowed for evaluation of the clinical effect of exebacase in a superiority-
design study with less likelihood of confounding by adverse medical occurrences unrelated to the disease 
under study which may occur at later timepoints. 
Key secondary and exploratory objectives were to estimate clinical outcome at Day 7, EOT, and TOC, 
estimate microbiologic outcome at Days 7 and 14, describe clinical outcomes in patients with MRSA and 
by diagnosis, describe post-dose immunological response to exebacase, and explore health resource 
utilization. Uncomplicated or complicated BSI and right- or left-sided endocarditis were mutually 
exclusive diagnoses for the analyses. Clinical response was defined as survival with improvement or 
resolution of attributable signs and symptoms, and without new signs or symptoms, new foci of infection, 
change in antibiotics due to non-response, complications of S. aureus, or further surgery or medical 
intervention to treat S. aureus. Microbiological response was defined as two consecutive blood cultures 
collected on different days yielding no S. aureus growth. 
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Safety assessments included adverse events (AEs), vital signs, electrocardiograms, and clinical laboratory 
tests. Treatment emergent AEs (TEAEs) were those with an onset or worsening of severity that occurred 
at or after administration of study drug through TOC. 
Statistics 
The study was designed to provide proof-of-concept and an initial assessment of efficacy and was not 
considered a confirmatory trial. The sample size of approximately 70 and 45 patients in the exebacase + 
antibiotics and antibiotics alone groups, respectively, provided at least 80% power to detect a treatment 
difference of 25 percentage points in clinical response at Day 14, based on expected clinical responder 
rates of 60% in the antibiotics alone group and 85% in the exebacase + antibiotics group. 
Clinical outcome at Day 14, as assessed by the Adjudication Committee, was the primary efficacy 
variable. For the primary analysis, once a patient was assessed as a clinical non-responder (i.e., failure) 
due to death, new metastatic foci, complications or surgery due to S. aureus, or change in antibiotics due 
to non-response, the patient was a clinical non-responder for all subsequent visits through TOC. The 
clinical responder rates at Day 14 were compared between treatment groups using Fisher's exact test. 
Statistical significance was based on a two-sided alpha level of 0.05. No adjustment was made for 
multiple comparisons as confirmatory inferential analyses were not conducted for secondary outcomes or 
subgroup analyses of clinical response at Day 14 (statistical comparisons were an ad hoc analysis). Two-
sided 90% confidence intervals for the difference in outcome rates between treatment groups were 
calculated using a continuity corrected Z-statistic. 
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Figure 1: Patient Disposition 
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Figure 2: Forest Plot of Clinical Responders by Diagnosis 
 
Abbreviations: BSI=bloodstream infection; cBSI=complicated bloodstream infection; CI=confidence interval; LIE=left-sided 
endocarditis; RIE=right-sided endocarditis. 
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Table 1. Baseline Disease Characteristics and Risk Factors/Comorbidities (mITT Population) 
 Total Population MRSA1 MSSA1 
 Exebacase + 
Antibiotics 
(N=71) 
n (%) 
Antibiotics 
Alone 
(N=45) 
n (%) 
Exebacase + 
Antibiotics 
(N=27) 
n (%) 
Antibiotics 
Alone 
(N=16) 
n (%) 
Exebacase + 
Antibiotics 
(N=44) 
n (%) 
Antibiotics 
Alone 
(N=30) 
n (%) 
       
Disease Characteristics       
Final Diagnosis by Adjudication Committee  
  Endocarditis 16 (22.5) 6 (13.3) 5 (18.5) 1 (6.3) 11 (25.0) 5 (16.7) 
      Right-sided endocarditis 5 (7.0) 3 (6.7) 2 (7.4) 1 (6.3) 3 (6.8) 2 (6.7) 
      Left-sided endocarditis 11 (15.5) 3 (6.7) 3 (11.1) 0 8 (18.2) 3 (10.0) 
  BSI 55 (77.5) 39 (86.7) 22 (81.5) 15 (93.8) 33 (75.0) 25 (83.3) 
      Complicated BSI 42 (59.2) 36 (80.0) 17 (63.0) 13 (81.3) 25 (56.8) 24 (80.0) 
      Uncomplicated BSI 13 (18.3) 3 (6.7) 5 (18.5) 2 (12.5) 8 (18.2) 1 (3.3) 
       
Primary source of infection in BSI patients2 
     Unknown 11 (20.0) 12 (30.8) 2 (9.1) 7 (46.7) 9 (27.3) 6 (24.0) 
     Skin and soft tissue 18 (32.7) 7 (17.9) 7 (31.8) 3 (20.0) 11 (33.3) 4 (16.0) 
     Intra-vascular 15 (27.3) 13 (33.3) 7 (31.8) 4 (26.7) 8 (24.2) 9 (36.0) 
     Other 11 (20.0) 7 (17.9) 6 (27.3) 1 (6.7) 5 (15.2) 6 (24.0) 
       
Risk Factors/Comorbidities 
Moderate/Severe renal 
impairment (<60 mL/min)3 
40 (56.3) 17 (37.8) 13 (48.1) 6 (37.5) 27 (61.4) 12 (40.0) 
Hemodialysis 21 (29.6) 8 (17.8) 9 (33.3) 1 (6.3) 12 (27.3) 7 (23.3) 
       
Hyperglycemia/Diabetes4 51 (71.8) 24 (53.3) 18 (66.7) 11 (68.8) 33 (75.0) 14 (46.7) 
  Poorly controlled diabetes5 20 (28.2) 8 (17.8) 4 (14.8) 3 (18.8) 16 (36.4) 5 (16.7) 
  Controlled diabetes 31 (43.7) 16 (35.6) 14 (51.9) 8 (50.0) 17 (38.6) 9 (30.0) 
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 Total Population MRSA1 MSSA1 
 Exebacase + 
Antibiotics 
(N=71) 
n (%) 
Antibiotics 
Alone 
(N=45) 
n (%) 
Exebacase + 
Antibiotics 
(N=27) 
n (%) 
Antibiotics 
Alone 
(N=16) 
n (%) 
Exebacase + 
Antibiotics 
(N=44) 
n (%) 
Antibiotics 
Alone 
(N=30) 
n (%) 
Recent injection drug use 6/62 (9.7) 5/39 (12.8) 4/23 (17.4) 2/13 (15.4) 2/39 (5.1) 3/27 (11.1) 
Preexisting valvular heart 
disease 
1/71 (1.4) 3/45 (6.7) 0 0 1/44 (2.3) 3/30 (10.0) 
Surgery within previous 
30 days 
11/71 (15.5) 5/45 (11.1) 7/27 (25.9) 1/16 (6.3) 4/44 (9.1) 4/30 (13.3) 
Extravascular foreign 
material 
9/71 (12.7) 9/45 (20.0) 3/27 (22.1) 4/16 (25.0) 6/44 (13.6) 5/30 (16.7) 
AIDS6 2/62 (3.2) 1/39 (2.6) 2/23 (8.7) 0 0 1/27 (3.7) 
SIRS6 45/62 (72.6) 27/39 (69.2) 17/23 (73.9) 11/13 (84.6) 28/39 (71.8) 16/27 (59.3) 
       
Cardiovascular4       
  Hypertension  53 (74.7) 23 (51.1) 20 (74.1) 7 (43.8) 33 (75.0) 17 (56.7) 
  Any cardiac history7 41 (57.8) 26 (57.8) 14 (51.9) 10 (62.5) 27 (61.4) 17 (56.7) 
  More than one cardiac 
diagnosis8 
27 (38.0) 17 (27.8) 9 (33.3) 6 (37.5) 18 (40.9) 12 (40.0) 
  Cardiac arrhythmias  23 (32.4) 16 (35.6) 6 (22.2) 7 (43.8) 17 (38.6) 10 (33.3) 
  Cardiac failure  23 (32.4) 12 (26.7) 8 (29.6) 5 (31.3) 15 (34.1) 8 (26.7) 
  Cardiomyopathy  29 (40.9) 17 (37.8) 8 (29.6) 7 (43.8) 21 (47.7) 11 (36.7) 
  Ischemic cardiac disease  14 (19.7) 10 (22.2) 4 (14.8) 3 (18.8) 10 (22.7) 8 (26.7) 
  Torsade de pointes 6 (8.5) 1 (2.2) 1 (3.7) 0 5 (11.4) 1 (3.3) 
       
Dyslipidemia  24 (33.8) 14 (31.1) 10 (37.0) 6 (37.5) 14 (31.8) 8 (26.7) 
       
Abbreviations: BSI=bloodstream infection. 
1. One patient in the antibiotics alone group had both MRSA and MSSA and was counted in both subgroups. 
2. Determined only for patients with BSI. 
29 
3. Creatinine clearance missing for 2 patients in the exebacase + antibiotics group and 1 patient in the antibiotics alone group. 
4. Comorbidities are determined from medical history and grouped based on standardized MedDRA queries. 
5. Poorly controlled diabetes as reported by the investigators. 
6. Risk factor not included in protocol amendment #4. 
7. Includes any medical history of cardiac arrhythmias, cardiac failure, cardiomyopathy, ischemic cardiac disease and torsade de 
pointes. 
8. Defined as more than one cardiac medical history term. 
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Table 2. Standard-of-Care Antibiotics Received (mITT Population) 
 Total Population MRSA1 MSSA1 
 Exebacase + 
Antibiotics 
(N=71) 
n (%) 
Antibiotics 
Alone 
(N=45) 
n (%) 
Exebacase + 
Antibiotics 
(N=27) 
n (%) 
Antibiotics 
Alone 
(N=16) 
n (%) 
Exebacase + 
Antibiotics 
(N=44) 
n (%) 
Antibiotics 
Alone 
(N=30) 
n (%) 
       
Standard-of-Care Antibiotic Exposure Through Day 142 
  Daptomycin 5 (11.1) 5 (7.0) 5 (18.5) 3 (18.8) 0 3 (10.0) 
  Vancomycin 24 (33.8) 17 (37.8) 21 (77.8) 13 (81.3) 3 (6.8) 4 (13.3) 
  Beta-lactam 
antibiotics 
42 (59.2) 23 (51.1) 1 (3.7) 0 41 (93.2) 23 (76.7) 
       
Total Duration of Standard-of-Care Antibiotics (Days)3 
Mean (SD) 36.0 (24.88) 32.7 (17.07) 40.2 (33.38) 33.4 (17.84) 33.5 (18.16) 32.9 (17.38) 
Median 31.0 30.0 31.0 35.0 30.5 30.0 
Minimum, 
maximum 
5, 184 4, 94 7, 184 2, 59 5, 91 4, 94 
       
Duration of Standard-of-Care Antibiotics from Start of Study Drug (Days)4 
Mean (SD) 33.3 (24.92) 30.5 (17.01) 36.6 (33.62) 31.3 (17.98) 31.5 (18.20) 30.8 (17.16) 
Median 29.0 29.0 29.0 32.5 29.5 28.5 
Minimum, 
maximum 
2, 181 2, 91 4, 181 2, 59 2, 88 3, 91 
       
Abbreviations: BSI=bloodstream infection. 
1. One patient in the antibiotics alone group had both MRSA and MSSA and was counted in both subgroups. 
2. Defined as the standard-of-care antibiotic received for the majority of the time from study drug administration through Day 14. 
3. Number of days from first antibiotic dose to last antibiotic dose, regardless of any changes in antibiotic agent and/or 
interruptions. 
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4. Number of days of antibiotic from start of study drug to last antibiotic dose, regardless of any changes in antibiotic agent 
and/or interruptions. 
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Table 3: Clinical Outcome Throughout the Study Assessed by Adjudication Committee by MRSA and MSSA 
Subgroup (mITT Population) 
 Total Population MRSA1 MSSA1 
 
Exebacase + 
Antibiotics 
 (N=71) 
n (%) 
Antibiotics 
Alone 
(N=45) 
n (%) 
Exebacase + 
Antibiotics 
 (N=27) 
n (%) 
Antibiotics 
Alone 
(N=16) 
n (%) 
 Exebacase + 
Antibiotics 
 (N=44) 
n (%) 
Antibiotics 
Alone 
(N=30) 
n (%) 
       
Day 14 (Primary Outcome)      
Responder2 50 (70.4) 27 (60.0) 20 (74.1) 5 (31.3) 30 (68.2) 22 (73.3) 
Difference (90% CI)3 10.4 [-6.3, 27.2] 42.8 [14.3, 71.4] -5.2 [-25.6, 15.3] 
p-value4 0.31 0.01 0.80 
Non-response 18 (25.4) 13 (28.9) 4 (14.8) 8 (50.0) 14 (31.8) 6 (20.0) 
Indeterminate 3 (4.2) 5 (11.1) 3 (11.1) 3 (18.8) 0 2 (6.7) 
       
Secondary Outcomes       
Day 7       
Responder2 51 (71.8) 31 (68.9) 18 (66.7) 7 (43.8) 33 (75.0) 25 (83.3) 
Non-response 17 (23.9) 11 (24.4) 7 (25.9) 8 (50.0) 10 (22.7) 2 (10.0) 
Indeterminate 3 (4.2) 3 (6.7) 2 (7.4) 1 (6.3) 1 (2.3) 2 (6.7) 
       
EOT       
Responder 44 (62.0) 28 (62.2) 14 (51.9) 7 (43.8)  30 (68.2) 21 (70.0) 
Non-response 22 (31.0) 13 (28.9) 8 (29.6) 8 (50.0) 14 (31.8) 6 (20.0) 
Indeterminate 5 (7.0) 4 (8.9) 5 (18.5) 1 (6.3) 0 3 (10.0) 
       
TOC       
Responder 39 (54.9) 24 (53.3) 13 (48.1) 5 (31.3) 26 (59.1) 19 (63.3) 
Non-response 25 (35.2) 15 (33.3) 8 (29.6) 9 (56.3) 17 (38.6) 7 (23.3) 
Indeterminate 7 (9.9) 6 (13.3) 6 (22.2) 2 (12.5) 1 (2.3) 4 913.3) 
       
33 
Abbreviations: CI=confidence interval; EOT=end-of-treatment with antibiotics; TOC=test-of-cure. 
1. One patient in the antibiotics alone group had both MRSA and MSSA and was counted in both subgroups. 
2. Responder=clinical outcome of improvement or response. 
3. CI for the difference in percentage improvement/response between exebacase + antibiotics and antibiotics alone groups 
calculated using a continuity corrected Z-statistic. 
4. P-value is based on Fisher's exact test. 
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Table 4: Overview of Adverse Events (Safety Population) 
 
Exebacase + 
Antibiotics 
(N=72) 
n (%) 
Antibiotics 
Alone 
(N=47) 
n (%) 
 
Number of patients with:    
TEAE through Day 7 48 (66.7) 30 (63.8) 
TEAE through TOC 64 (88.9) 40 (85.1) 
Events occurring in ≥8% through TOC in either treatment group   
Urinary tract infection 8 (11.1) 6 (12.8) 
Constipation 9 (12.5) 5 (10.6) 
Diarrhea 8 (11.1) 3 (6.4) 
Headache 7 (9.7) 4 (8.5) 
Anemia 6 (8.3) 4 (8.5) 
Cardiac murmur 6 (8.3) 1 (2.1) 
Edema peripheral 6 (8.3) 4 (8.5) 
Nausea 6 (8.3) 3 (6.4) 
Death NOS 1 (1.4) 4 (8.5) 
Abdominal pain 0 5 (10.6) 
   
Serious TEAE through TOC 34 (47.2) 23 (48.9) 
Serious TEAE through Day 180 45 (62.5) 28 (59.6) 
   
TEAE related to study drug 8 (11.1) 4 (8.5) 
Serious TEAE related to study drug 1 (1.4) 0 
   
TEAE leading to study drug discontinuation/withdrawal 0 0 
TEAE of hypersensitivity to exebacase 0 NA 
   
Death through Day 30 7 (9.7) 6 (12.8) 
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Exebacase + 
Antibiotics 
(N=72) 
n (%) 
Antibiotics 
Alone 
(N=47) 
n (%) 
Death through TOC1 14 (19.4) 7 (14.9) 
Death through Day 180 17 (23.6) 9 (19.1) 
 
Abbreviations: TEAE=treatment-emergent adverse event; TOC=test-of-cure; NA=not applicable; NOS=not otherwise specified. 
Note: Denominator is all patients in the safety population within each treatment group. 
1. All deaths through TOC occurred prior to Day 60, so this represents Day 60 mortality. 
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Table 5: Immunogenicity: Treatment-Emergent ADA and IgE (Safety Population) 
Parameter 
CF-301 
(N=72) 
n (%) 
Placebo 
(N=47) 
n (%) 
CF-301 ADA-positive at baseline 15/72 (20.8%) 7/47 (14.9) 
CF-301 ADA-negative at baseline 57/72 (79.2) 40/47 (85.1)
CF-301 ADA-negative at baseline and with NO post-dose sample 5 8 
CF-301 ADA-negative at baseline and with at least 1 post-dose sample 52 32 
No treatment-emergent ADA 15 (28.8) 24 (75.0) 
Treatment-emergent positive ADA 37 (71.2) 8 (25.0) 
Persistence1 15 (28.8) 3 (9.4) 
Transient 3 (5.8) 4 (12.5) 
Indeterminate (no Day 180 sample) 19 (36.5) 1 (3.1) 
IgE-positive at baseline2 1/72 (1.4) 0/46 (0) 
IgE-negative at baseline2 71/72 (98.6) 46/46 (100)
IgE-negative at baseline and with NO post-dose sample 6 9 
IgE-negative at baseline and with at least 1 post-dose sample 65 37 
No treatment-emergent IgE 56 (86.1) 36 (97.3) 
Treatment-emergent IgE 9 (13.9) 1 (2.7) 
Persistence (positive to Day 180) 3 (4.6) 0 
Transient (negative result after positive result) 3 (4.6) 1 (2.7) 
Indeterminate (no result after single positive result) 3 (4.6) 0 
Abbreviations: ADA=antidrug antibody; IgE=immunoglobulin E. 
Notes: Percentages are based on the number of patients with negative baseline and at least 1 post-baseline sample. 
Treatment-emergent ADA/IgE was defined as negative ADA/IgE at baseline and emergence of positive ADA/IgE after dosing. 
1. One patient had treatment-emergent ADA that emerged on Day 65 and persisted through Day 187. One patient had treatment-
emergent ADA that emerged on Day 62 and persisted through Day 176. 
2. One patient in the placebo group was missing the baseline IgE sample. 
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Table 6: Health Resource Utilization in US Patients (mITT Population) 
 All US Patients MRSA1 MSSA1 
 
Exebacase + 
Antibiotics 
(N=57) 
n (%) 
Antibiotics 
Alone 
(N=37) 
n (%) 
Exebacase + 
Antibiotics 
(N=26) 
n (%) 
Antibiotics 
Alone 
(N=15) 
n (%) 
Exebacase + 
Antibiotics 
(N=31) 
n (%) 
Antibiotics 
Alone 
(N=23) 
n (%) 
       
In-hospital mortality 3 (5.3) 2 (5.4) 1 (3.9) 2 (13.3) 2 (6.5) 0 
Patients discharged alive 54 35 25 13 29 23 
Number of hospital days from dose of study drug to hospital discharge 
n 54 34 25 13 29 22 
Median 7.0 7.0 6.0 10.0 8.0 7.0 
Minimum, maximum 2, 69 2, 51 2, 69 5, 51 3, 66 2, 46 
30-day all-cause readmission2 12 (22.2) 13 (37.1) 4 (16.0) 4 (30.8) 8 (27.6) 10 (43.5) 
30-day S. aureus readmission2 3 (5.6) 2 (5.7) 2 (8.0) 2 (15.4) 1 (3.4) 0 
       
1. One patient in the antibiotics alone group had both MRSA and MSSA and was counted in both subgroups. 
2. Denominator is number of patients discharged alive. 
 
